[ midday review strategy]
The index rose after opening higher in early trading, and the gem index rose nearly 3%. As of midday closing, the Shanghai index rose 1.29%, the Shenzhen Composite Index rose 2.09% and the gem index rose 2.89%.
In terms of sectors, real estate development, building materials, cement, securities and other sectors led the increase, while agricultural planting, coal, chemical fertilizer, oil and gas exploitation and other sectors led the decline.
On the disk, the real estate sector strengthened again, and the sector lifted the tide of the limit, 6 Shanxi Taigang Stainless Steel Co.Ltd(000825) even the sector, and the building materials and cement related to real estate also rose collectively. Brokerage stocks rebounded, Hongta Securities Co.Ltd(601236) limit. The agricultural related sectors that rose sharply yesterday fell into adjustment today.
Overall, individual stocks rose more and fell less, and more than 3000 stocks in the two cities rose. The half day turnover of Shanghai and Shenzhen stock markets reached 568.6 billion, up from 35.2 billion in the morning of the previous trading day.
In terms of northbound funds, the Shanghai Stock connect had a net inflow of 3.265 billion in early trading and the Shenzhen Stock connect had a net inflow of 3.408 billion in early trading.
[message side]
1. Lu Hongzhou, Shenzhen Third People’s Hospital: Pfizer oral medicine has shown preliminary efficacy in small-scale clinical practice in Shenzhen, but further research is needed
The reporter learned on the evening of March 29 that a small-scale clinical study of 24 patients with covid-19 by Professor Lu Hongzhou’s team of the national infectious disease clinical research center of Shenzhen Third People’s Hospital showed that the average nucleic acid CT value of these patients: the ORF gene CT value increased from 19.365 to 35.92 five days after treatment, which met the discharge standard, and the N gene increased from 18.46 to 34.22 five days after treatment, Close to discharge criteria. Lu Hongzhou’s team began to use paxlovid for these patients from March 24 He told reporters that although the preliminary results showed that the drug efficacy was accurate, it still needs to continue research and expand the sample size to make the results more accurate. Lu Hongzhou also said that further comparative statistical results will be released soon.
